Louisville researchers move closer to potential treatment for gum disease

NewsGuard 100/100 Score

University of Louisville researchers recently received a patent on a synthetic biochemical compound and its variants, moving science closer to a treatment for gum disease. This discovery could lead to the formulation of a mouth rinse or tooth varnish to prevent the pathogen, P. gingivalis from colonizing in the mouth and establishing itself orally.

Donald Demuth, Ph.D., associate dean for research and enterprise, UofL School of Dentistry, and Frederick Luzzio, Ph.D., professor, UofL College of Arts & Sciences, Department of Chemistry, developed and tested 40 different molecular compounds, and the three most potent compounds are being developed further.

This patent builds on the previous work of Demuth and other UofL dental school researchers who developed a series of peptides, the building blocks of protein in a cell, that prevent interaction between P. gingivalis and S. gordonii.

"When P. gingivalis enters the oral environment, it initially interacts with the bacterium S. gordonii - an otherwise benign organism - in order to lay the ground work to propagate and ultimately gain a foothold below the gum line, leading to periodontal disease," Demuth said.

Demuth found that administering the peptide in an animal model prevented P. gingivalis related bone loss - the clinical symptom of periodontal disease - and prevented the spread of the bacterium in the mouth. He says creating peptides is expensive, but synthetic compounds that mimic the active peptides are easier to formulate and less costly to produce on a large scale.

Luzzio and Demuth hope to improve the potency and stability of the three synthetic molecular structures, and eventually gain approval for a clinical trial.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers develop precise drugs to target HIV's Nef protein